Brief: Aptinyx Appoints Gilmore O’Neill To Board Of Directors
Brief: Aptinyx Secures $50 Million Growth Capital Credit Facility
Brief: Aptinyx Reports Second Quarter Financial Results
Aptinyx Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aptinyx Reports Qtrly Net Loss Per Share $0.29
Aptinyx Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Aptinyx Provides Update On Nyx-783 Development Program For The Treatment Of Post-Traumatic Stress Disorder
Aptinyx Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aptinyx Reports First Quarter 2021 Financial Results And Highlights
Aptinyx Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Aptinyx Appoints Joan W. Miller, M.D. To Board Of Directors
Brief: Aptinyx Presents Additional Positive Data From Phase 2 Exploratory Study Of NYX-783 In PTSD At Society Of Biological Psychiatry Annual Meeting
U.S. STOCKS ON THE MOVE-Phunware Inc, Niu Technologies, Cara Therapeutics, gold miners
U.S. STOCKS ON THE MOVE-Ebang, Airbnb Inc, Scienjoy and Greenbrier Companies
U.S. STOCKS ON THE MOVE-Illumina, Crexendo Inc, Xcel Brands, Romeo Power
Aptinyx: Jumps on restarting trial of dementia treatment
Brief: Aptinyx Recommences Phase 2 Study Of NYX-458 In Patients With Cognitive Impairment Associated With Parkinson’s Disease Dementia And Dementia With Lewy Bodies
Brief: Aptinyx Posts Qtrly Loss Per Share Basic And Diluted $0.20
Brief: Invus Public Equities L.P Reports 9.7% Passive Stake In Aptinyx Inc As Of January 20, 2021 - SEC Filing